Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-11-09

Clinical Trial Update: Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 study of LYS006 in mild to moderate ulcerative colitis was terminated; results were posted on 2023-11-09.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LYS006

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Colitis, Ulcerative | Phase 2 | Status: TERMINATED | Results posted: 2023-11-09